- The US FDA inspected NATCO Pharma's formulation plant at Kothur, Hyderabad, from 12 to 20 November 2026 and issued 7 observations in a Form 483.
- Natco says the observations are procedural and that it is confident of addressing them within the set timelines.
- Separately, the FDA has classified its August inspection of Natco's Visakhapatnam formulation plant, which had 4 observations, as Voluntary Action Indicated (VAI).
What it means for Natco's business
Fixes to make at Kothur
- Natco now has to answer the 7 observations and put fixes in place. That takes management time and some spending; the filing gives no cost.
The outcome is not known yet
- A Form 483 is not the FDA's final word. The FDA later classifies the inspection, and that classification decides whether there is any wider effect on the plant.
Visakhapatnam moves on
- VAI means the FDA does not plan regulatory action over the August inspection, so the Visakhapatnam plant moves past it.
What the filing says
Kothur inspection
- Plant: formulation manufacturing facility at Kothur, Hyderabad.
- Inspection: 12 to 20 November 2026, by the US FDA.
- Result: 7 observations in a Form 483. Natco says they are procedural and that it will address them within the stipulated timelines.
- Natco filed this on 21 November 2026.
Visakhapatnam inspection
- Plant: finished dosage formulations (FDF) plant at Parawada, Visakhapatnam, Andhra Pradesh.
- Inspection: 17 to 21 August 2026, which ended with 4 observations in a Form 483.
- Now: Natco has received the Establishment Inspection Report (EIR), classifying the inspection as VAI. It filed this on 20 November 2026.
Why it matters
What a Form 483 is
- A Form 483 lists conditions FDA inspectors saw that may break its manufacturing rules. The company replies with how it will fix them.
What VAI means
- Voluntary Action Indicated means the FDA found issues but does not plan regulatory action; the company fixes them itself. It is the middle of the FDA's three inspection outcomes.
What the filing does not say
- It does not describe the 7 observations, which products the Kothur plant makes for the US, or how much of Natco's sales come from it.
What to watch next
- Natco's reply to the FDA, and the FDA's classification of the Kothur inspection.
Funds that hold Natco
- Tata Small Cap Fund1.7% of the fund
- Nippon India Growth Mid Cap Fund0.17% of the fund
- Bandhan Small Cap Fund0.03% of the fund
From each fund house's October 2026 portfolio.
Source: Exchange filings
Natco: questions
What did the US FDA find at Natco's Kothur plant?
It issued 7 observations in a Form 483 after inspecting the formulation plant from 12 to 20 November 2026. Natco says they are procedural, according to its 21 November 2026 filing.
What does the Kothur inspection mean for Natco's business?
Natco must answer the observations and put fixes in place. The wider effect depends on how the FDA classifies the inspection, which is not yet known. Its Visakhapatnam plant has meanwhile been cleared with VAI status.
What happened at Natco's Visakhapatnam plant?
The FDA classified its August 2026 inspection, which had 4 observations, as Voluntary Action Indicated (VAI), Natco said on 20 November 2026.
What happens next for Natco's Kothur plant?
Natco will respond to the observations within the set timelines, and the FDA will then classify the inspection.
This page is educational research based on company filings. It is not a recommendation to buy or sell any security or fund, or personalised investment advice. Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, enlistment with IAASB and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.


